John Murphy, CEO The COVID-19 Long haul Foundation<\/p>\n\n\n\n
More than six years after the emergence of SARS-CoV-2, the question \u201cWill we ever find a cure for COVID-19?\u201d remains deceptively difficult to answer. The difficulty arises because COVID-19 is no longer a single clinical entity. It encompasses acute SARS-CoV-2 infection, severe inflammatory and vascular disease, persistent or recurrent viral infection in selected individuals, post-acute sequelae of SARS-CoV-2 infection (Long COVID), and chronic organ dysfunction that may persist after viral replication has ceased. These conditions have different biological mechanisms and therefore cannot reasonably be expected to respond to a single therapeutic strategy.<\/p>\n\n\n\n
The development of highly effective vaccines, monoclonal antibodies during earlier phases of the pandemic, direct-acting antivirals, immunomodulators, anticoagulant strategies, and improved supportive care has transformed acute COVID-19 from the catastrophic disease of 2020 into a substantially more manageable infection for many patients. Nevertheless, these interventions generally suppress disease rather than eliminate SARS-CoV-2 from the human population. Viral evolution, antigenic drift, tissue compartmentalization, immunological heterogeneity, and the possibility of persistent viral reservoirs complicate the prospect of sterilizing immunity or universal eradication.[1\u20134]<\/p>\n\n\n\n
The more difficult question concerns Long COVID. Increasing evidence implicates several potentially overlapping mechanisms, including persistent viral material or replication in tissue reservoirs, immune dysregulation, autoimmunity, endothelial and microvascular dysfunction, autonomic dysfunction, altered cellular metabolism, mitochondrial abnormalities, and reactivation of latent or persistent pathogens.[5\u20139] Whether one or several of these mechanisms are causal in particular patients remains an active area of investigation.<\/p>\n\n\n\n
A realistic scientific objective therefore may not be a single \u201cCOVID cure,\u201d but rather a therapeutic architecture capable of preventing infection, rapidly terminating viral replication, eliminating persistent viral reservoirs when they exist, suppressing pathological immune responses, repairing endothelial and metabolic injury, and reversing established organ dysfunction. Such an approach is biologically plausible. Whether it will ultimately produce complete cures for all forms of COVID-19 remains uncertain. Nevertheless, the history of infectious disease provides substantial reason for optimism: diseases once regarded as incurable have repeatedly become preventable, treatable, or eradicable when their biological mechanisms were sufficiently understood.<\/p>\n\n\n\n
The phrase \u201ccure for COVID-19\u201d conceals several fundamentally different objectives.<\/p>\n\n\n\n
A treatment can cure an acute infection without preventing reinfection. A vaccine can prevent severe disease without completely preventing infection. An antiviral can suppress viral replication without eliminating every infected cell. An immunomodulatory drug can prevent death from inflammatory injury without eliminating the virus. A treatment for Long COVID may restore function even if no residual virus remains.<\/p>\n\n\n\n
Consequently, the scientific question should be reformulated:<\/p>\n\n\n\n
Can SARS-CoV-2 infection be completely eliminated from an individual, its pathological consequences reversed, and the continuing circulation of the virus eventually interrupted?<\/strong><\/p>\n\n\n\n The answer is increasingly encouraging for some components of this question and considerably less certain for others.<\/p>\n\n\n\n SARS-CoV-2 remains globally established and continues to evolve. A 2026 review in Nature Reviews Microbiology<\/em> emphasizes that more than five years after its emergence, the virus continues to circulate and undergo substantial evolutionary change.<\/p>\n\n\n\n Yet the medical landscape is profoundly different from that of early 2020. Physicians now possess antiviral agents, immunomodulators, extensive clinical experience, molecular diagnostics, genomic surveillance, vaccines, and an enormous body of biological knowledge.<\/p>\n\n\n\n The problem is no longer ignorance.<\/p>\n\n\n\n It is complexity.<\/p>\n\n\n\n The most defensible answer is that acute COVID-19 is already curable in a substantial proportion of patients<\/strong>.<\/p>\n\n\n\n That statement requires qualification.<\/p>\n\n\n\n \u201cNirmatrelvir\u2013ritonavir,\u201d remdesivir, and other antiviral approaches can substantially reduce progression to severe disease in appropriately selected patients. WHO continues to maintain living therapeutic guidelines because treatment recommendations evolve with evidence, variants, baseline risk, drug interactions, and patient characteristics.[10]<\/p>\n\n\n\n Nirmatrelvir inhibits the SARS-CoV-2 main protease, thereby interfering with processing of viral polyproteins essential for replication. Remdesivir inhibits the viral RNA-dependent RNA polymerase.<\/p>\n\n\n\n These drugs attack the virus itself rather than merely treating its consequences.<\/p>\n\n\n\n That distinction is fundamental.<\/p>\n\n\n\n The history of infectious disease repeatedly demonstrates that direct interference with pathogen replication can convert a previously dangerous infection into a manageable disease. HIV is the most dramatic modern example. Combination antiretroviral therapy does not ordinarily eradicate HIV, but it can suppress viral replication to levels at which patients may live for decades.<\/p>\n\n\n\n SARS-CoV-2 presents a substantially more favorable therapeutic problem than HIV because it does not establish the same type of permanent genomic reservoir in host chromosomes.<\/p>\n\n\n\n That creates a theoretical possibility that true eradication from an individual may be substantially more achievable for SARS-CoV-2 than for HIV<\/strong>.<\/p>\n\n\n\n But theoretical possibility is not equivalent to demonstrated clinical reality.<\/p>\n\n\n\n The central limitation of current antiviral treatment is timing.<\/p>\n\n\n\n SARS-CoV-2 replication is most intense early in infection. Severe disease, however, may subsequently become dominated by host inflammatory, endothelial, thrombotic, metabolic, and tissue-injury processes.<\/p>\n\n\n\n Thus the disease can evolve through several stages:<\/p>\n\n\n\n viral replication \u2192 innate immune activation \u2192 endothelial and vascular injury \u2192 inflammatory amplification \u2192 tissue damage \u2192 repair or persistent dysfunction.<\/strong><\/p>\n\n\n\n An antiviral administered after substantial tissue injury has developed may successfully eliminate replicating virus without immediately reversing the pathological consequences.<\/p>\n\n\n\n This principle explains why antiviral therapy can be extremely valuable early in disease while being insufficient as a universal treatment for late-stage disease.<\/p>\n\n\n\n The WHO clinical-management framework therefore emphasizes risk assessment, disease severity, supportive treatment, and appropriate therapeutics rather than assuming that every manifestation of COVID-19 represents ongoing viral replication.<\/p>\n\n\n\n A second obstacle is evolutionary.<\/p>\n\n\n\n Every replication cycle creates opportunities for mutation. Variants possessing a selective advantage can spread through populations containing increasingly sophisticated immunity from vaccination, prior infection, or both.<\/p>\n\n\n\n Recent genomic studies demonstrate continued evolution of SARS-CoV-2 under immune pressure, particularly involving the spike protein, which remains the principal target of neutralizing antibodies.[2,3]<\/p>\n\n\n\n This creates a fundamental asymmetry.<\/p>\n\n\n\n The human immune system must recognize a moving target.<\/p>\n\n\n\n A successful universal vaccine or sterilizing antibody strategy must therefore recognize viral structures that are sufficiently conserved that the virus cannot easily alter them without compromising its own biological fitness.<\/p>\n\n\n\n This is why next-generation vaccine research increasingly seeks:<\/p>\n\n\n\n The ultimate goal is not merely a vaccine that reduces hospitalization.<\/p>\n\n\n\n It is a vaccine capable of preventing productive infection across a wide range of future SARS-CoV-2 variants<\/strong>.<\/p>\n\n\n\n That is a much higher scientific bar.<\/p>\n\n\n\n Perhaps the most consequential development in COVID-19 research has been the growing investigation of viral persistence.<\/p>\n\n\n\n The conventional model of an acute respiratory viral infection is straightforward:<\/p>\n\n\n\n infection \u2192 replication \u2192 immune clearance \u2192 recovery.<\/p>\n\n\n\n But some investigations have identified SARS-CoV-2 RNA, proteins, or other viral material in tissues weeks or months after acute infection.<\/p>\n\n\n\n The biological interpretation remains controversial.<\/p>\n\n\n\n Detection of viral RNA does not necessarily demonstrate replication-competent virus. Detection of viral protein does not necessarily establish productive infection. Conversely, the absence of detectable virus in blood does not exclude viral persistence in a tissue compartment.<\/p>\n\n\n\n The distinction is critical.<\/p>\n\n\n\n A person may have:<\/p>\n\n\n\n These possibilities may coexist among different patients.<\/p>\n\n\n\n The question therefore cannot be reduced to \u201cIs the virus still there?\u201d<\/p>\n\n\n\n It must become:<\/p>\n\n\n\n Is replication-competent SARS-CoV-2 persisting in a biologically meaningful reservoir, and does that persistence contribute causally to disease?<\/strong><\/p>\n\n\n\n That question is one of the central unresolved issues in Long COVID research.<\/p>\n\n\n\n Acute COVID-19 and Long COVID are not necessarily the same disease separated merely by time.<\/p>\n\n\n\n Long COVID is a heterogeneous syndrome involving multiple physiological systems. Contemporary investigations have implicated neurological, cardiovascular, pulmonary, gastrointestinal, autonomic, immune, metabolic, vascular, and musculoskeletal abnormalities.<\/p>\n\n\n\n Several mechanistic models have consequently emerged.<\/p>\n\n\n\n Persistent viral material could continually stimulate innate and adaptive immune responses.<\/p>\n\n\n\n The initial infection could leave the immune system in a persistently abnormal state.<\/p>\n\n\n\n In susceptible individuals, infection might generate antibodies or cellular responses directed against host structures.<\/p>\n\n\n\n Microvascular injury could impair oxygen delivery, vascular regulation, and tissue perfusion.<\/p>\n\n\n\n Damage or dysregulation of autonomic pathways could produce abnormalities in heart rate, blood pressure, gastrointestinal function, thermoregulation, and exercise tolerance.<\/p>\n\n\n\n Persistent alterations in energy metabolism could contribute to fatigue, exercise intolerance, and cognitive dysfunction.<\/p>\n\n\n\n Some patients may simply be living with the consequences of organ damage incurred during the acute infection.<\/p>\n\n\n\n This final possibility may ultimately prove the most important.<\/p>\n\n\n\n Long COVID may not be one disease.<\/p>\n\n\n\n It may be a collection of post-infectious syndromes produced by different biological pathways.<\/p>\n\n\n\n This is one of the most intriguing therapeutic possibilities.<\/p>\n\n\n\n Suppose a subgroup of patients has persistent replication-competent SARS-CoV-2 in tissue.<\/p>\n\n\n\n If persistent replication is responsible for continued antigen exposure, immune activation, endothelial injury, or other downstream abnormalities, then sufficiently effective antiviral treatment\u2014or a combination of antivirals capable of penetrating relevant tissue reservoirs\u2014could theoretically produce remission.<\/p>\n\n\n\n But this hypothesis has not yet been established as a universal explanation for Long COVID.<\/p>\n\n\n\n Indeed, the 2026 European Respiratory Society clinical practice guideline concluded that evidence concerning pharmacological treatment of Long COVID remains limited and of variable quality. It specifically suggests against using nirmatrelvir\u2013ritonavir as treatment for established Long COVID in adults, reflecting the absence of convincing clinical evidence that routine antiviral therapy reverses established disease.<\/p>\n\n\n\n This does not<\/strong> demonstrate that viral persistence is irrelevant.<\/p>\n\n\n\n It demonstrates that a hypothesis about pathogenesis is not automatically a proven treatment.<\/p>\n\n\n\n The distinction is essential.<\/p>\n\n\n\n Even if SARS-CoV-2 were completely eliminated from the body, disease could continue.<\/p>\n\n\n\n This phenomenon is common throughout medicine.<\/p>\n\n\n\n Eradicating a bacterium does not necessarily reverse the scar it produced.<\/p>\n\n\n\n Eliminating a virus does not necessarily restore destroyed neurons.<\/p>\n\n\n\n Removing an inflammatory stimulus does not necessarily reconstruct damaged vascular architecture.<\/p>\n\n\n\n Stopping myocardial inflammation does not automatically regenerate myocardial tissue.<\/p>\n\n\n\n Thus, a genuine cure for some patients with Long COVID may require regenerative medicine rather than antiviral medicine<\/strong>.<\/p>\n\n\n\n This could eventually involve:<\/p>\n\n\n\n In other words, the future \u201cCOVID cure\u201d may be a sequence of treatments rather than a single pill.<\/p>\n\n\n\n The immune system presents another paradox.<\/p>\n\n\n\n An inadequate immune response permits viral replication.<\/p>\n\n\n\n An excessive or dysregulated response can produce tissue injury.<\/p>\n\n\n\n Therefore, the ideal therapy must suppress pathological immunity without suppressing protective antiviral immunity<\/strong>.<\/p>\n\n\n\n This distinction explains why broad immunosuppression can be lifesaving in selected severe COVID-19 patients but potentially counterproductive during uncontrolled viral replication.<\/p>\n\n\n\n Future therapy may therefore move toward precision immunology.<\/p>\n\n\n\n Instead of broadly suppressing inflammation, physicians may eventually identify the dominant pathological pathway in an individual patient and selectively interrupt it.<\/p>\n\n\n\n Potential targets include:<\/p>\n\n\n\n The challenge will be determining which pathway is abnormal in which patient and at what stage of disease<\/strong>.<\/p>\n\n\n\n The answer is scientifically uncertain but not pessimistic.<\/p>\n\n\n\n The present generation of vaccines has demonstrated that vaccination can substantially reduce severe disease, hospitalization, and death. But sterilizing immunity\u2014complete prevention of infection\u2014has been much more difficult to achieve.<\/p>\n\n\n\n There are biological reasons.<\/p>\n\n\n\n SARS-CoV-2 initially infects mucosal surfaces, particularly the upper respiratory tract. Systemic immunity generated by intramuscular vaccination does not necessarily produce the same magnitude or durability of immune protection at those surfaces.<\/p>\n\n\n\n Consequently, the next generation of vaccines may need to generate strong mucosal immunity in addition to systemic immunity.<\/p>\n\n\n\n Intranasal or other mucosal vaccine approaches therefore represent an important avenue of research.<\/p>\n\n\n\n A truly transformative vaccine would ideally accomplish four objectives:<\/p>\n\n\n\n Such a vaccine would not merely reduce the burden of COVID-19.<\/p>\n\n\n\n It could fundamentally change its epidemiology.<\/p>\n\n\n\n Eradication is a much higher standard than curing individual patients.<\/p>\n\n\n\n Humanity has achieved global eradication of only one human infectious disease: smallpox.<\/p>\n\n\n\n Poliovirus has come extraordinarily close but has not yet been completely eliminated.<\/p>\n\n\n\n Several characteristics made smallpox unusually eradicable:<\/p>\n\n\n\n SARS-CoV-2 possesses characteristics that make eradication considerably more difficult.<\/p>\n\n\n\n It can be transmitted by asymptomatic or minimally symptomatic individuals.<\/p>\n\n\n\n It infects humans repeatedly.<\/p>\n\n\n\n It evolves rapidly.<\/p>\n\n\n\n Immunity against infection is imperfect and wanes.<\/p>\n\n\n\n And animal reservoirs may complicate eradication strategies.<\/p>\n\n\n\n For these reasons, global eradication of SARS-CoV-2 is currently unlikely<\/strong>.<\/p>\n\n\n\n But eradication of severe disease is an entirely different proposition.<\/p>\n\n\n\n Humanity may eventually reach a point at which infection produces little more than transient illness in most immunologically competent individuals while effective treatment prevents serious disease in vulnerable populations.<\/p>\n\n\n\n That would not constitute eradication.<\/p>\n\n\n\n It would constitute functional control<\/strong>.<\/p>\n\n\n\n HIV provides both an encouraging analogy and a warning.<\/p>\n\n\n\n Modern antiretroviral therapy transformed HIV from a rapidly fatal disease into a chronic manageable infection for many patients.<\/p>\n\n\n\n Yet HIV remains difficult to eradicate because proviral DNA becomes integrated into long-lived host cells.<\/p>\n\n\n\n SARS-CoV-2 does not ordinarily establish such a permanent integrated reservoir.<\/p>\n\n\n\n This is encouraging.<\/p>\n\n\n\n If persistent SARS-CoV-2 infection is demonstrated to involve replication-competent tissue reservoirs, there is at least a theoretical possibility that combinations of potent antivirals could eventually eliminate those reservoirs.<\/p>\n\n\n\n The difficulty would then become one of drug penetration and anatomical compartmentalization<\/strong>.<\/p>\n\n\n\n A virus hidden within a relatively inaccessible tissue compartment may behave very differently from virus freely circulating in the respiratory tract.<\/p>\n\n\n\n The ultimate antiviral therefore may need to combine:<\/p>\n\n\n\n high potency + broad variant coverage + tissue penetration + prolonged exposure + a high genetic barrier to resistance.<\/strong><\/p>\n\n\n\n Combination therapy may become particularly important if persistent infection is proven to occur in immunocompromised or otherwise susceptible individuals.<\/p>\n\n\n\n The future of COVID treatment may resemble oncology and HIV more than traditional infectious-disease monotherapy.<\/p>\n\n\n\n One drug may inhibit viral protease.<\/p>\n\n\n\n Another may inhibit polymerase.<\/p>\n\n\n\n A third could target viral entry.<\/p>\n\n\n\n A fourth might stimulate an appropriately targeted antiviral immune response.<\/p>\n\n\n\n Still another might address the inflammatory or vascular consequences of infection.<\/p>\n\n\n\n Such combinations could make viral escape more difficult.<\/p>\n\n\n\n The scientific rationale is straightforward:<\/p>\n\n\n\n If a virus must acquire several independent mutations simultaneously to escape multiple mechanisms of inhibition, the evolutionary barrier to resistance rises.<\/p>\n\n\n\n This principle has already shaped antiviral medicine in other diseases.<\/p>\n\n\n\n Whether it will ultimately be required for persistent SARS-CoV-2 infection remains an empirical question.<\/p>\n\n\n\n One of the most underappreciated components of a future cure is time<\/strong>.<\/p>\n\n\n\n A disease may be far easier to cure before irreversible tissue injury occurs.<\/p>\n\n\n\n The ideal future diagnostic system might determine, within hours or days:<\/p>\n\n\n\n Treatment could then become individualized.<\/p>\n\n\n\n A patient with high viral replication but minimal inflammation might receive intensive antiviral therapy.<\/p>\n\n\n\n A patient with declining viral burden but severe inflammatory activation might receive carefully selected immunomodulation.<\/p>\n\n\n\n A patient with persistent antigen months later might undergo reservoir-directed treatment.<\/p>\n\n\n\n A patient with no detectable virus but demonstrable autonomic or endothelial dysfunction might receive entirely different therapy.<\/p>\n\n\n\n This would represent a fundamental transition from syndrome-based medicine to mechanism-based COVID medicine<\/strong>.<\/p>\n\n\n\n The current Long COVID research enterprise is still relatively young.<\/p>\n\n\n\n The NIH RECOVER program continues clinical trials examining treatments for different Long COVID symptom clusters, including autonomic dysfunction, and its next phase of treatment studies is expanding the therapeutic portfolio.<\/p>\n\n\n\n That is important because Long COVID cannot reasonably be expected to yield to a single treatment.<\/p>\n\n\n\n A patient whose principal pathology is autonomic dysfunction may require a very different intervention from one whose dominant problem is persistent pulmonary disease, autoimmune pathology, endothelial dysfunction, or post-viral neurological injury.<\/p>\n\n\n\n The future therefore belongs to phenotyping<\/strong>.<\/p>\n\n\n\n The question will increasingly become not:<\/p>\n\n\n\n \u201cWhat treats Long COVID?\u201d<\/p>\n<\/blockquote>\n\n\n\n but:<\/p>\n\n\n\n \u201cWhat mechanism is driving this patient’s Long COVID?\u201d<\/p>\n<\/blockquote>\n\n\n\n That conceptual shift could prove decisive.<\/p>\n\n\n\n A scientifically meaningful cure for COVID-19 could ultimately be defined at several levels.<\/p>\n\n\n\n The virus becomes undetectable and symptoms resolve.<\/p>\n\n\n\n Infection occurs but does not produce clinically important organ injury.<\/p>\n\n\n\n The immune system eliminates SARS-CoV-2 from all clinically relevant tissue compartments.<\/p>\n\n\n\n Established Long COVID manifestations resolve even after the acute infection has ended.<\/p>\n\n\n\n Reinfection becomes impossible or clinically insignificant.<\/p>\n\n\n\n Human transmission disappears permanently.<\/p>\n\n\n\n These are six different scientific achievements.<\/p>\n\n\n\n It is entirely possible that humanity will achieve the first five without ever achieving the sixth.<\/p>\n\n\n\n The most scientifically defensible answer is:<\/p>\n\n\n\n Probably\u2014but not necessarily one cure, and not necessarily one cure for everyone.<\/strong><\/p>\n\n\n\n There is little reason to believe that SARS-CoV-2 is biologically invincible.<\/p>\n\n\n\n The virus has vulnerabilities:<\/p>\n\n\n\n The major uncertainty concerns what happens after the initial infection.<\/p>\n\n\n\n For many individuals, the virus appears to be cleared and recovery occurs.<\/p>\n\n\n\n For others, substantial tissue injury may persist.<\/p>\n\n\n\n For some, immune abnormalities may become self-sustaining.<\/p>\n\n\n\n For some, viral persistence may contribute.<\/p>\n\n\n\n And for others, several mechanisms may coexist.<\/p>\n\n\n\n The challenge is therefore not simply discovering a more powerful antiviral.<\/p>\n\n\n\n It is discovering which biological mechanism is maintaining disease in each patient<\/strong>.<\/p>\n\n\n\n A future comprehensive COVID strategy could eventually resemble the following sequence:<\/p>\n\n\n\n Broad-spectrum vaccines, potentially including mucosal vaccination, provide durable immunity against infection and severe disease.<\/p>\n\n\n\n Rapid molecular and antigenic testing identifies infection before substantial tissue injury develops.<\/p>\n\n\n\n Potent oral or inhaled antivirals rapidly reduce viral replication.<\/p>\n\n\n\n Biomarkers identify patients developing pathological inflammation and direct targeted treatment.<\/p>\n\n\n\n Patients with demonstrated persistent replication receive combination therapies capable of reaching relevant tissue compartments.<\/p>\n\n\n\n Patients with established post-viral injury receive mechanism-specific therapies directed toward neurological, vascular, pulmonary, cardiac, metabolic, or autonomic dysfunction.<\/p>\n\n\n\n Biomarkers identify patients at risk of persistent disease before irreversible damage develops.<\/p>\n\n\n\n This would be far more sophisticated than the concept of a single \u201cCOVID pill.\u201d<\/p>\n\n\n\n Several questions will determine whether a definitive cure becomes possible.<\/p>\n\n\n\n First:<\/strong> How frequently does replication-competent SARS-CoV-2 persist after acute infection?<\/p>\n\n\n\n Second:<\/strong> In which tissues does it persist?<\/p>\n\n\n\n Third:<\/strong> Does viral persistence actually cause Long COVID, or is it merely one component of a larger post-infectious process?<\/p>\n\n\n\n Fourth:<\/strong> Which patients develop persistent disease, and why?<\/p>\n\n\n\n Fifth:<\/strong> Can tissue reservoirs be eradicated safely?<\/p>\n\n\n\n Sixth:<\/strong> Can established neurological, vascular, pulmonary, and metabolic injury be reversed?<\/p>\n\n\n\n Seventh:<\/strong> Can future vaccines produce sufficiently broad and durable mucosal immunity?<\/p>\n\n\n\n Eighth:<\/strong> Can viral evolution be sufficiently constrained to prevent continual immune escape?<\/p>\n\n\n\n Each answer will influence what \u201ccure\u201d ultimately means.<\/p>\n\n\n\n The most probable future is neither complete defeat of SARS-CoV-2 nor perpetual helplessness before it.<\/p>\n\n\n\n It is progressive medical domestication of the virus<\/strong>.<\/p>\n\n\n\n Acute mortality will continue to decline.<\/p>\n\n\n\n Antivirals will become more potent, convenient, and broadly active.<\/p>\n\n\n\n Vaccines will probably become more variant-resistant.<\/p>\n\n\n\n Diagnostics will become faster.<\/p>\n\n\n\n Persistent infection will become better characterized.<\/p>\n\n\n\n Long COVID will increasingly be divided into mechanistic subtypes.<\/p>\n\n\n\n Some forms may become curable.<\/p>\n\n\n\n Others may become manageable.<\/p>\n\n\n\n And some irreversible injuries will remain permanent.<\/p>\n\n\n\n This is precisely what occurred with many other infectious diseases.<\/p>\n\n\n\n Tuberculosis can be cured in most patients, but destroyed lung tissue may remain.<\/p>\n\n\n\n Polio infection can be prevented, but established paralysis may be irreversible.<\/p>\n\n\n\n Hepatitis C can now be cured with direct-acting antivirals, yet cirrhosis and cancer risk may persist after viral eradication.<\/p>\n\n\n\n The distinction between eliminating the pathogen<\/strong> and repairing the damage caused by the pathogen<\/strong> is therefore central to the future of COVID medicine.<\/p>\n\n\n\n The question \u201cWill we ever find a cure for COVID-19?\u201d should not be answered with either complacency or despair.<\/p>\n\n\n\n The evidence supports neither.<\/p>\n\n\n\n We have already demonstrated that SARS-CoV-2 replication can be therapeutically suppressed and that severe disease can frequently be prevented or treated. Modern clinical management is radically more effective than it was during the first year of the pandemic.<\/p>\n\n\n\n But a universal cure remains elusive because COVID-19 is not simply a viral replication disorder.<\/p>\n\n\n\n It can become a vascular disease, an inflammatory disease, an immunological disease, a neurological disease, a pulmonary disease, an autonomic disorder, a metabolic disorder, or a post-infectious multisystem syndrome.<\/p>\n\n\n\n Consequently, the ultimate cure may not be a single molecule.<\/p>\n\n\n\n It may be a therapeutic system<\/strong>.<\/p>\n\n\n\n That system would prevent infection when possible, identify infection immediately when prevention fails, eliminate viral replication before substantial tissue injury occurs, eradicate persistent viral reservoirs when they exist, selectively suppress pathological immune responses, and repair the biological damage that remains after the virus has disappeared.<\/p>\n\n\n\n The scientific basis for such a strategy is increasingly credible, although many essential components remain unproven.<\/p>\n\n\n\n The more difficult question\u2014whether humanity can eradicate SARS-CoV-2 from the planet\u2014is considerably less certain.<\/p>\n\n\n\n But eradication may not be necessary.<\/p>\n\n\n\n If science can transform SARS-CoV-2 into an infection that is rapidly eliminated, rarely produces severe disease, does not generate persistent pathological syndromes, and can be effectively treated when complications occur, then medicine will have accomplished something approaching a cure in the clinically meaningful sense.<\/p>\n\n\n\n The ultimate victory over COVID-19 may therefore not come when SARS-CoV-2 disappears.<\/p>\n\n\n\n It may come when the virus can no longer determine the fate of the person it infects.<\/strong><\/p>\n\n\n\n None declared.<\/p>\n\n\n\n No external funding was received for preparation of this review.<\/p>\n\n\n\n Conceptualization, literature synthesis, interpretation, and manuscript preparation: author. John Murphy<\/p>\n\n\n\n This article is a scientific narrative review and does not constitute individualized medical advice. Therapeutic decisions should be based on contemporary clinical guidelines, individual patient characteristics, contraindications, drug interactions, and the treating clinician’s assessment.<\/p>\n","protected":false},"excerpt":{"rendered":" John Murphy, CEO The COVID-19 Long haul Foundation From Antiviral Suppression to Viral Eradication, Persistent Infection, and the Reversal of Long COVID Abstract More than six years after the emergence […]<\/p>\n","protected":false},"author":2,"featured_media":16137,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101,1320,289,592],"tags":[],"class_list":["post-16123","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19","category-long-cov","category-long-haul-disease","category-treatments"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/16123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16123"}],"version-history":[{"count":3,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/16123\/revisions"}],"predecessor-version":[{"id":16138,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/16123\/revisions\/16138"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/16137"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n\n\n\nI. The First Meaning of Cure: Can We Cure Acute COVID-19?<\/h5>\n\n\n\n
Antiviral therapy has already changed the answer<\/h5>\n\n\n\n
\n\n\n\nII. Why Antiviral Therapy Is Not the Same as a Cure<\/h5>\n\n\n\n
\n\n\n\nIII. The Moving Target: SARS-CoV-2 Evolution<\/h5>\n\n\n\n
\n
\n\n\n\nIV. The Most Difficult Question: Does SARS-CoV-2 Persist?<\/h5>\n\n\n\n
\n
\n\n\n\nV. Why Long COVID Changes the Definition of \u201cCure\u201d<\/h5>\n\n\n\n
1. Viral persistence<\/h5>\n\n\n\n
2. Immune dysregulation<\/h5>\n\n\n\n
3. Autoimmunity<\/h5>\n\n\n\n
4. Endothelial dysfunction<\/h5>\n\n\n\n
5. Autonomic dysfunction<\/h5>\n\n\n\n
6. Metabolic and mitochondrial dysfunction<\/h5>\n\n\n\n
7. Tissue injury<\/h5>\n\n\n\n
8. Multiple mechanisms simultaneously<\/h5>\n\n\n\n
\n\n\n\nVI. If Viral Persistence Causes Some Long COVID, Antivirals Could Become Curative<\/h5>\n\n\n\n
\n\n\n\nVII. The Second Great Challenge: Damage May Persist After the Virus Is Gone<\/h5>\n\n\n\n
\n
\n\n\n\nVIII. Could Immune Therapy Cure COVID?<\/h5>\n\n\n\n
\n
\n\n\n\nIX. Could a Vaccine Eventually Prevent COVID Completely?<\/h5>\n\n\n\n
\n
\n\n\n\nX. Can SARS-CoV-2 Be Eradicated?<\/h5>\n\n\n\n
\n
\n\n\n\nXI. The HIV Analogy\u2014and Its Limits<\/h5>\n\n\n\n
\n\n\n\nXII. The Importance of Combination Therapy<\/h5>\n\n\n\n
\n\n\n\nXIII. The Future May Depend on Earlier Diagnosis<\/h5>\n\n\n\n
\n
\n\n\n\nXIV. The Long COVID Therapeutic Revolution Has Barely Begun<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXV. What Would a True Cure Look Like?<\/h5>\n\n\n\n
Level 1: Acute viral clearance<\/h5>\n\n\n\n
Level 2: Prevention of severe disease<\/h5>\n\n\n\n
Level 3: Prevention of persistent infection<\/h5>\n\n\n\n
Level 4: Reversal of post-viral pathology<\/h5>\n\n\n\n
Level 5: Durable immunity<\/h5>\n\n\n\n
Level 6: Population-level eradication<\/h5>\n\n\n\n
\n\n\n\nXVI. Will We Ever Find a Cure?<\/h5>\n\n\n\n
\n
\n\n\n\nXVII. A Plausible Future Therapeutic Architecture<\/h5>\n\n\n\n
Phase 1 \u2014 Prevention<\/h5>\n\n\n\n
Phase 2 \u2014 Early detection<\/h5>\n\n\n\n
Phase 3 \u2014 Early viral suppression<\/h5>\n\n\n\n
Phase 4 \u2014 Precision immunomodulation<\/h5>\n\n\n\n
Phase 5 \u2014 Reservoir elimination<\/h5>\n\n\n\n
Phase 6 \u2014 Tissue repair<\/h5>\n\n\n\n
Phase 7 \u2014 Long-term surveillance<\/h5>\n\n\n\n
\n\n\n\nXVIII. The Most Important Scientific Unknowns<\/h5>\n\n\n\n
\n\n\n\nXIX. The Most Likely Outcome<\/h5>\n\n\n\n
\n\n\n\nConclusion<\/h5>\n\n\n\n
\n\n\n\nReferences and Footnotes<\/h5>\n\n\n\n
\n
Conflict of Interest<\/h5>\n\n\n\n
Funding<\/h5>\n\n\n\n
Author Contributions<\/h5>\n\n\n\n
Disclaimer<\/h5>\n\n\n\n